In the first quarter of 2015, inVentiv Consulting surveyed 105 licensing professionals, capturing expectations for deal activity, supply and demand for assets at different stages of development, and approaches to valuation. The results of that survey provide a forward-looking view into what dealmakers anticipate will happen in licensing and acquisitions over the upcoming year. The results of the 2015 Dealmakers’ Intentions Study notes that buyers’ demand for preclinical and phase III assets overshadows supply across several therapeutic areas, which will likely result in significant increase in asset value this year. The study also found sellers with a more optimistic outlook than buyers for the balance of 2015. While the record pace of licensing/acquisitions has continued into 2015, there have been early signals of a potential slowdown. These signals include increased expectations of acquisitions with earn-outs over outright acquisitions and greater financing options available to emerging companies, which pose a viable alternative to licensing.
Dealmakers’ Intentions presents conclusions that are crucial for C-suite executives, as well as executives responsible for dealmaking strategy and the business development function.
A summary of the study results was presented during our Super Session at the BIO International Convention. Pharmaceutical Executive magazine also hosted an editorial roundtable to highlight the study.
Download a white paper summarizing the survey results.
However, the results of this study are much more impactful and applicable to any company's business situation when they are delivered in person. Request that an inVentiv Health Consulting team member present the full survey results to your organization and discuss its implications for your business.
Results from prior Dealmakers' Intentions studies can be found in our Landmark Studies section.